Ablative MR-guided RT achieved 95% local control in GEP-NETs
Among 20 mostly metastatic GEP-NET patients, MR-guided ablative RT achieved 95% local control with acute grade 3 toxicity in 10%.
Among 20 mostly metastatic GEP-NET patients, MR-guided ablative RT achieved 95% local control with acute grade 3 toxicity in 10%.
In one cadaveric RCC plan, stable 1-cm perirenal separation reduced large-bowel Dmax from 34.5 to 22.1 Gy.
Seven patients completed 60 Gy with no recurrences, grade ≥3 skin toxicity, fibrosis, cartilage necrosis, or nasal contour deformation at early follow-up.
Four patients completed 54 Gy after airway reconstruction without graft-related toxicity or local recurrence during early follow-up.
Quality of life remained stable after 30–37.5 Gy in three fractions, while symptomatic patients achieved 59% pain response at 24 weeks.
Compared with 8 Gy in one fraction, five- and ten-fraction regimens were associated with approximately two- and threefold higher odds of lymphopenia.
Sequential 55 Gy in 20 fractions achieved 62% three-year locoregional control, outperforming conventionally fractionated sequential chemoradiotherapy without greater toxicity.
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
A child developed hemorrhagic colitis after only 12.6 Gy(RBE), suggesting preceding intensive systemic therapy may increase bowel vulnerability.
After propensity matching, overall survival was similar between surgery plus adjuvant RT and definitive RT, while disease-control differences remained non-significant.
Despite a mean whole-heart dose below 9 Gy, eleven cardiac substructures averaged above 10 Gy, and targeted replanning substantially reduced coronary exposure.
Loss of the Y chromosome tracked with greater cancer-cell survival after irradiation and worse outcomes in selected radiotherapy-treated male patients.
All 50 proton SBRT fractions were completed, with online adaptation used in 84% to restore target coverage or resolve OAR violations.
Random forest best predicted ovarian dose after transposition, but all models deteriorated sharply when ovaries lay within approximately 17 mm of the PTV.
Patient-specific feasibility guidance improved target homogeneity and reduced rectal low-dose exposure after automated RapidPlan optimization.